Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
Head and neck cancer therapy toxicities greater in women
Cristina V et al. JAMA Oncol. 2018 May 24. doi: 10.1001/jamaoncol.2018.1080.
Key clinical point: Risks of adverse events were significantly higher in women treated with fluorouracil with or without irinotecan.
Major finding: Compared with men, women had significantly higher rates of all-grade alopecia, anemia, cholinergic syndrome, constipation, cramping, lethargy, leukopenia, nausea, neutropenia, stomatitis, and vomiting.
Study details: A retrospective analysis of treatment-emergent adverse events for 2,974 participants in the PETACC-3 trial conducted by the EORTC Gastrointestinal Group.
Disclosures: The authors reported disclosures related to Amgen, Bayer, Boehringer, Bristol-Myers Squibb, Celgene, Ipsen, Lilly, Merck, Merck KgA, Novartis, Pfizer, Roche, Sanofi, Servier, and Shire.
Source: Cristina V et al. JAMA Oncol. 2018 May 24. doi: 10.1001/jamaoncol.2018.1080.
Cristina V et al. JAMA Oncol. 2018 May 24. doi: 10.1001/jamaoncol.2018.1080.